Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Colorectal Neoplasms × trilaciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 9 Breast Neoplasms 8 Triple Negative Breast Neoplasms 7 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Osteosarcoma 2 Uterine Cervical Neoplasms 1 Sarcoma, Ewing 1 Pathologic Complete Response 1 Neutropenia 1 Neoplasms 1 NSCLC 1 Myelosuppression 1 Limited Stage Small Cell Lung Cancer 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Advanced Squamous Non-Small-Cell Lung Cancer 1

Interventions

Fluorouracil 494 Bevacizumab 469 Oxaliplatin 445 Leucovorin 436 Irinotecan 406 Cetuximab 315 Capecitabine 312 pembrolizumab 141 Folfox protocol 125 Panitumumab 116 regorafenib 105 Colonoscopy 88 IFL protocol 81 Nivolumab 79 Drug Therapy 75 trifluridine tipiracil drug combination 73 Radiotherapy 66 HMPL-013 64 Blood Specimen Collection 52 Gemcitabine 49 Neoadjuvant Therapy 45 Specimen Handling 44 Standard of Care 42 Magnetic Resonance Spectroscopy 42 Biopsy 42 Chemotherapy, Adjuvant 40 atezolizumab 38 Trifluridine 38 Surveys and Questionnaires 38 Cyclophosphamide 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04607668 2024-11-26

PRESERVE1

G1 Therapeutics, Inc.

Phase 3 Terminated

326 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡